Results 11 to 20 of about 350 (140)
Adjuvant Razoxane in Resectable Colorectal Cancer
, 1980 Survival of patients with resectable colorectal cancer (CRC) has not been materially influenced during the last 20 years by either adjuvant chemotherapy or any new surgical development. Attempts to influence survival in CRC by adjuvant chemotherapy are limited by the fact that of the few drugs that have shown activity in the advanced form of this ...
J. Gilbert +4 more
openaire +2 more sources
The promise and challenges of cell therapy for psoriasis*
British Journal of Dermatology, Volume 185, Issue 5, Page 887-898, November 2021., 2021 Summary The management of moderate‐to‐severe psoriasis has been transformed by the introduction of biological therapies. These medicines, particularly those targeting interleukin (IL)‐17 and IL‐23p19, can offer clear or nearly clear skin for the majority of patients with psoriasis, with good long‐term drug survival.
S.M. Lwin +2 more
wiley +1 more source
The preparation and crystal and molecular structure of the complex cis-PtCl2(razoxane)
Inorganica Chimica Acta, 1998 Kevin B Nolan
exaly +2 more sources
Determination of razoxane by high-performance liquid chromatography
Journal of Chromatography B: Biomedical Sciences and Applications, 1983 M, Collins +3 more
openaire +3 more sources
Combination of radiotherapy and razoxane (ICRF 159) for chondrosarcoma [PDF]
Cancer, 1979 Eight patients with 12 chondrosarcomas were treated with radiation and razoxane (ICRF 159). Two tumors in 1 patient progressed unequivocally, 3 tumors in 3 patients showed no change, and 7 tumors in 5 patients had complete or partial (more than 50%) regressions.
R D, Ryall +3 more
openaire +2 more sources
Metal-Based Drugs, Volume 4, Issue 4, Page 199-205, 1997., 1997 Use of the antitumor drug doxorubicin is limited by cardiomyopathic side‐effects which are believed to be due to iron‐mediated hydroxyl radical generation. Dexrazoxane reduces this cardiotoxicity, possibly by removal of iron from doxorubicin by the EDTA‐like hydrolysis product of dexrazoxane, ADR‐925. However, EDTA‐diimides like dexrazoxane, previously
Thomas J. Magliery +3 more
wiley +1 more source
Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. [PDF]
Br J Cancer, 2003 Anderson H +6 more
europepmc +2 more sources
Metal-Based Drugs, Volume 1, Issue 4, Page 321-328, 1994., 1994 The synthesis and crystal and molecular structures of the platinum(II) complex Pt(HL)Cl where H2L is the diacid diamide –[CH2N(CH2COOH)CH2CONH2] 2, a hydrolytic metabolite of an antitumour active bis(3,5‐dioxopiperazin‐1‐yl)alkane are reported. The complex is square planar and contains HL− as a tridentate 2N (amino), O (carboxylate) donor. The metal to
Kevin B. Nolan +5 more
wiley +1 more source
Metal-Based Drugs, Volume 1, Issue 1, Page 41-63, 1994., 1993 In this paper we report a review of the results obtained in the last few years by our group in the development of ruthenium(III) complexes characterized by the presence of sulfoxide ligands and endowed with antitumor properties. In particular, we will focus on ruthenates of general formula Na[trans‐RuCl4(R1R2SO)(L)], where R1R2SO = dimethylsulfoxide ...
G. Mestroni +5 more
wiley +1 more source